MAGE-A4-Responsive Plasma Cells Promote Non-Small Cell Lung Cancer.
Dominique ArmstrongCheng-Yen ChangMonica J HongLinda GreenWilliam HudsonYichao ShenLi-Zhen SongSheetal JammiBenjamin CasalChad J CreightonAlexandre CariseyXiang H F ZhangNeil J McKennaSung Wook KangHyun-Sung LeeDavid B CorryFarrah KheradmandPublished in: bioRxiv : the preprint server for biology (2024)
Adaptive immunity is critical to eliminate malignant cells, while multiple tumor-intrinsic factors can alter this protective function. Melanoma antigen-A4 (MAGE-A4), a cancer-testis antigen, is expressed in several solid tumors and correlates with poor survival in non-small cell lung cancer (NSCLC), but its role in altering antitumor immunity remains unclear. We found that expression of MAGE-A4 was highly associated with the loss of PTEN , a tumor suppressor, in human NSCLC. Here we show that constitutive expression of human MAGE-A4 combined with the loss of Pten in mouse airway epithelial cells results in metastatic adenocarcinoma enriched in CD138 + CXCR4 + plasma cells, predominantly expressing IgA. Consistently, human NSCLC expressing MAGE-A4 showed increased CD138 + IgA + plasma cell density surrounding tumors. The abrogation of MAGE-A4-responsive plasma cells (MARPs) decreased tumor burden, increased T cell infiltration and activation, and reduced CD163 + CD206 + macrophages in mouse lungs. These findings suggest MAGE-A4 promotes NSCLC tumorigenesis, in part, through the recruitment and retention of IgA + MARPs in the lungs.
Keyphrases
- induced apoptosis
- small cell lung cancer
- cell cycle arrest
- endothelial cells
- squamous cell carcinoma
- poor prognosis
- endoplasmic reticulum stress
- cell proliferation
- cell death
- signaling pathway
- radiation therapy
- induced pluripotent stem cells
- drug delivery
- cancer therapy
- young adults
- binding protein
- cell migration
- african american